The product is used to delay the progression of children’s myopia aged 6-12 with spherical lenses of -1.00D to -4.00D (astigmatism≤1.50D and anisometropia≤1.50D)
Promotes tear secretion in patients with dry eyes. For patients with reduced tear secretion caused by ocular inflammation associated with keratoconjunctivitis sicca.
For keratohelcosis and corneal injury due to various causes, corneal bum caused by acid or alkali, bullous keratitis, neuroparalytic keratitis, as well as corneal and conjunctival degeneration.
For keratohelcosis and corneal injury due to various causes, corneal bum caused by acid or alkali, bullous keratitis, neuroparalytic keratitis, as well as corneal and conjunctival degeneration.
R & D Innovation Sustains Business Development
The R & D team of Xingqi relies on independent innovation and synergizes the efforts of the industry, universities and research institutions to deliver safe and effective drugs for eye diseases. On the basis of the National Enterprise Technology Center, Liaoning Province Enterprise Technology Center, Liaoning Province Ophthalmic Medication Technology Innovation Center, Liaoning Province Children and Adolescents Myopia Prevention and Control Engineering Research Center and the Joint Innovation Center Between Liaoning Institute of Industrial Technology and Xingqi, we have developed comprehensive strengths in ophthalmic medication R & D and innovation and established an ophthalmic drug R & D platform for conventional ophthalmic preparations, instant gels, sustained-release preparations, pharmaceutical packaging compatibility and pharmacodynamics, pharmacokinetics and toxicology of ophthalmic medications. Meanwhile, we have worked closely with Chinese and international research institutes, medical institutions and ophthalmologists to promote the transformation of our scientific and technological achievements.
